Search | Clinical Trials Finder

Conditions: Ovarian Cancer
Interventions: Decitabine, Carboplatin, Paclitaxel, Selinexor; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Oakland, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Interventions: Atezolizumab, Biospecimen Collection, Conventional Surgery, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Tocilizumab; Biological · Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 110
States / cities: Anaheim, California • Bellflower, California • Los Angeles, California + 89 more

Conditions: Osteoarthritis, Knee
Interventions: Bone Marrow Derived MSCs, Corticosteroid, Bone Marrow Aspirate; Biological · Drug · Device
Lead sponsor: Next Generation Regenerative Medicine LLC; Network
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Chesterfield, Missouri • Steubenville, Ohio • Salt Lake City, Utah

Conditions: Parkinson's Disease
Interventions: nicotine, placebo comparator; Drug · Other
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 83 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more

Conditions: Acne Vulgaris
Interventions: Doxycycline 100mg, Aczone 5% gel; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 12 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Multiple Myeloma
Interventions: Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 6
States / cities: Duarte, California • Irvine, California • Denver, Colorado + 3 more

Conditions: Hypotension, Headache
Interventions: Wiley Spinal Catheter, Spinal Anesthesia Group (SAG); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy Volunteers
Interventions: Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg, Alprazolam, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Uveitis, JIA
Interventions: Adalimumab, Placebo; Biological · Other
Lead sponsor: Nisha Acharya; Other
Eligibility: 2 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Alzheimer Disease
Interventions: Pepinemab, Placebo; Drug
Lead sponsor: Vaccinex Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 14
States / cities: San Diego, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more

Conditions: MULTIPLE MYELOMA
Interventions: Velcade; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Ulcerative Colitis (UC)
Interventions: XmAb942, Placebo; Biological · Drug
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 29
States / cities: Scottsdale, Arizona • Bradenton, Florida • Brandon, Florida + 24 more

Conditions: Hypercholesterolemia
Interventions: alirocumab SAR236553 (REGN727); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Healthy Volunteer
Interventions: RO5093151, atazanavir, ketoconazole, rifampicin, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Merritt Island, Florida

Conditions: Inactivity, Physical
Interventions: Behavior Change Technique Package; Behavioral
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Stroke
Interventions: WATCHMAN LAAC Device Implant, Single Antiplatelet Therapy or No Therapy (Control); Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 71
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more

Conditions: Schizophrenia
Interventions: SEP-380135, Quinidine Gluconate; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Solid Tumors
Interventions: Sterile Compound C31510 for Injection; Drug
Lead sponsor: BPGbio; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Healthy Volunteers
Interventions: IW-3300, Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants
Interventions: vepdegestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Oral contraceptive, Acetaminophen; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Insomnia, Fatigue
Interventions: BBT-I, Control, Armodafinil; Behavioral · Drug
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Post Operative Pain
Interventions: Bupivacaine 0.5% Injectable Solution, Ropivacaine 0.2% Injectable Solution, 1.3% liposomal bupivacaine (Exparel), ambIT Infusion Pump; Drug · Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Somerset, New Jersey

Search by objective public record fields.

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study Comparing Two Spinal Techniques for for Cesarean Delivery Anesthesia

A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

Adalimumab in JIA-associated Uveitis Stopping Trial

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

BCT Intervention For Walking Habit Among Caregivers of People With AD/ADRD

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women

Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

Management of Insomnia in Breast Cancer Patients

Post Operative Infusion Pump Pain Study